LICENSE AGREEMENT University of Michigan File 3718License Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks
This Agreement is effective as of October 16, 2007 (the “Effective Date”), between Nephrion (“LICENSEE”) having the address in Article 13 below, and the Regents of the University of Michigan, a constitutional corporation of the State of Michigan (“MICHIGAN”). LICENSEE and MICHIGAN agree as follows:
SEVENTH AMENDMENT TO LICENSE AGREEMENT (University of Michigan Files 3718)License Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks
This Amendment (“Amendment”), dated March 20, 2022 (“Effective Date”), is by and between SeaStar Medical, Inc. (“LICENSEE”) and the Regents of the University of Michigan (“MICHIGAN”).
CYTOPHERX, INC. WARRANT TO PURCHASE PREFERRED STOCK No. [•] [•]LMF Acquisition Opportunities Inc • May 16th, 2022 • Blank checks • Delaware
THIS CERTIFIES THAT, for value received, [•], with its principal office at [•], or assigns (the “Holder”), is entitled to subscribe for and purchase from CYTOPHERX, INC., a Delaware corporation, with its principal office at 401 West Morgan Road, Ann Arbor, MI 48108 (the “Company”) Exercise Shares at the Exercise Price (each as defined below and each subject to adjustment as provided herein). This Warrant is being issued as one of a series of warrants (the “Warrants”) pursuant to the terms of the Note and Warrant Purchase Agreement, dated [•], as amended, by and among the Company and the Purchasers named therein (the “Purchase Agreement”). Unless indicated otherwise, the aggregate number of Exercise Shares that Holder may purchase by exercising this warrant is equal to (a) one hundred percent (100%), multiplied by (B) such Holder’s Supplemental Warrant Coverage Amount (as defined in the Purchase Agreement), divided by (C) the Conversion Price (as defined in the Supplemental Notes), subj
SIXTH AMENDMENT TO LICENSE AGREEMENT (University of Michigan Files 3718)License Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks
This Amendment (“Amendment”), dated August 24, 2020 (“Effective Date”), is by and between SeaStar Medical, Inc. (“LICENSEE”) and the Regents of the University of Michigan (“MICHIGAN”).
FIFTH AMENDMENT TO LICENSE AGREEMENT (University of Michigan Files 3718)License Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks
This Amendment (“Amendment”), dated December 19 2019 (“Effective Date”), is by and between SeaStar Medical, Inc. (“LICENSEE”) and the Regents of the University of Michigan (“MICHIGAN”).
FOURTH AMENDMENT TO LICENSE AGREEMENT OTT File 0671License Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks
This amendment, dated June 20, 2016, is by and between Cytopherx, Inc. (“LICENSEE”) and the Regents of the University of Michigan (“MICHIGAN”).
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks
This amendment, dated 22 March 2011, is by and between Cytopherx, Inc. (“LICENSEE”) and the Regents of the University of Michigan (“MICHIGAN”).
SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks
This amendment, dated 9 August, 2013, is by and between Cytopherx (“LICENSEE”) and the Regents of the University of Michigan (“MICHIGAN”).
THIRD AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks
WHEREAS, Nephrion, now doing business as Cytopherx (“LICENSEE”) and MICHIGAN entered into a license agreement dated 16 October 2007, entered into a First Amendment 22 March 2011, and entered into a Second Amendment 8 August 2013 (collectively the “License Agreement”); and
AMENDED AND RESTATED LICENSE AGREEMENT MICHIGAN FILE 469\671\1621\1936\2175\2305License Agreement • May 16th, 2022 • LMF Acquisition Opportunities Inc • Blank checks • Michigan
This is an Agreement between Nephrion, Inc., a corporation incorporated in the State of Delaware, with offices located at 206 S. Fifth, Suite 550, Ann Arbor, Michigan 48104 (as assignee of RenaMed Biologics, Inc. formerly known as Nephros Therapeutics, Inc.) (“NEPHRION”), and the Regents of the University of Michigan, a constitutional corporation of the State of Michigan (“MICHIGAN”). This Agreement is effective as of the date executed by both NEPHRION and MICHIGAN (the “Effective Date”). NEPHRION and MICHIGAN agree as follows:
